Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 40 thumbs up ...

Dude, quit putting words in my mouth that were never spoken. What I said was that since the moment in time when the Pohl signed the Master Agreement with Moore and TPL, it hasn't been PTSC's responibility to "monetize" the MMP. Got it? That summarizes my response to this question from BUSHleague:

"How has the BoD enhanced the monetization of the MMP and what has been the result of those efforts vis-a-vis shareholder value, over the short-term, mid-term, and long-term?"

Sheesh.

SGE

BTW, I disagree with the rest of your post, but refuse to rehash 5-6 years of history with someone who has only been posting here since 7/8/09.

Share
New Message
Please login to post a reply